Company / Accounts Receivable
Cytosorbents Corp Accounts Receivable History
FY2011-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$3.9M
FY2018
5-year range
$648.9K / $3.9M
FY2014-FY2018
Trend
+78.8%
vs FY2017
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has increased for 3 consecutive years, from $648,869 in FY2015 to $4M in FY2018.
Based on SEC 10-K filings.
$4M in FY2018 with a 5-year CAGR of +54.2%.
Improved from $1M to $4M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +82.5%
- 5-Year CAGR
- +54.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- Cytosorbents Corp's accounts receivable has grown for 3 consecutive years.
- 5-year CAGR of +54.2%, indicating consistent growth.
- In FY2018, accounts receivable increased 78.8% year-over-year.
- Lowest accounts receivable in the period was in FY2011.
Company context
Key Data Points
- Altman Z-Score -4.61 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2018 | $3.9M | +78.8% |
| FY2017 | $2.2M | +53.9% |
| FY2016 | $1.4M | +120.9% |
| FY2015 | $648.9K | -20.8% |
| FY2014 | $819.2K | +80.8% |
| FY2013 | $453.0K | +774.9% |
| FY2012 | $51.8K | +43.5% |
| FY2011 | $36.1K | - |
As of FY2018 · SEC 10-K · Updated Jun 24, 2026